よむ、つかう、まなぶ。
○医薬品の新規薬価収載について 総－５－３ (24 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/shingi2/0000212500_00223.html |
| 出典情報 | 中央社会保険医療協議会 総会（第564回 11／15）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
.
1
2
3
4
5
6
7
8
9
10
11
12
Guh DP, Zhang W, Bansback N, Amarsi Z, Birmingham CL, Anis AH. The incidence of
co-morbidities related to obesity and overweight: a systematic review and meta-analysis.
BMC Public Health. 2009;9:88.
World Health Organization. Obesity: Preventing and Managing the Global Epidemic.
Report of a WHO Consultation. World Health Organisation Geneva, Switzerland. 2000.
Prospective Studies C, Whitlock G, Lewington S, Sherliker P, Clarke R, Emberson J, et al.
Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of
57 prospective studies. Lancet. 2009;373(9669):1083-96.
Must A, Spadano J, Coakley EH, Field AE, Colditz G, Dietz WH. The disease burden
associated with overweight and obesity. JAMA. 1999;282(16):1523-9.
Saab J, Salvatore SP. Evaluating the cause of death in obese individuals: a ten-year
medical autopsy study. J Obes. 2015;695374.
厚生労働省健康局. 令和元年国民健康・栄養調査結果の概要. 2020 年 10 月.
https://www.mhlw.go.jp/content/10900000/000687163.pdf
日本肥満学会. 肥満症診療ガイドライン. ライフサイエンス出版. 2022 年 12 月
The Examination Committee of Criteria for ‘Obesity Disease’ in Japan. New Criteria for
‘Obesity Disease’ in Japan. Circ J. 2002;66(11):987-92.
Orskov C, Wettergren A, Holst JJ. Secretion of the incretin hormones glucagon-like
peptide-1 and gastric inhibitory polypeptide correlates with insulin secretion in normal
man throughout the day. Scandinavian journal of gastroenterology. 1996;31(7):665-70.
Flint A, Raben A, Astrup A, Holst JJ. Glucagon-like peptide 1 promotes satiety and
suppresses energy intake in humans. J Clin Invest. 1998;101(3):515-20.
Gutzwiller JP, Drewe J, Göke B, Schmidt H, Rohrer B, Lareida J, et al. Glucagon-like
peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type
2. Am J Physiol. 1999;276(5):R1541-4.
Verdich C, Flint A, Gutzwiller JP, Näslund E, Beglinger C, Hellström PM, et al. A metaanalysis of the effect of glucagon-like peptide-1 (7-36) amide on ad libitum energy intake
in humans. J Clin Endocrinol Metab. 2001;86(9):4382-9.
23
1
2
3
4
5
6
7
8
9
10
11
12
Guh DP, Zhang W, Bansback N, Amarsi Z, Birmingham CL, Anis AH. The incidence of
co-morbidities related to obesity and overweight: a systematic review and meta-analysis.
BMC Public Health. 2009;9:88.
World Health Organization. Obesity: Preventing and Managing the Global Epidemic.
Report of a WHO Consultation. World Health Organisation Geneva, Switzerland. 2000.
Prospective Studies C, Whitlock G, Lewington S, Sherliker P, Clarke R, Emberson J, et al.
Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of
57 prospective studies. Lancet. 2009;373(9669):1083-96.
Must A, Spadano J, Coakley EH, Field AE, Colditz G, Dietz WH. The disease burden
associated with overweight and obesity. JAMA. 1999;282(16):1523-9.
Saab J, Salvatore SP. Evaluating the cause of death in obese individuals: a ten-year
medical autopsy study. J Obes. 2015;695374.
厚生労働省健康局. 令和元年国民健康・栄養調査結果の概要. 2020 年 10 月.
https://www.mhlw.go.jp/content/10900000/000687163.pdf
日本肥満学会. 肥満症診療ガイドライン. ライフサイエンス出版. 2022 年 12 月
The Examination Committee of Criteria for ‘Obesity Disease’ in Japan. New Criteria for
‘Obesity Disease’ in Japan. Circ J. 2002;66(11):987-92.
Orskov C, Wettergren A, Holst JJ. Secretion of the incretin hormones glucagon-like
peptide-1 and gastric inhibitory polypeptide correlates with insulin secretion in normal
man throughout the day. Scandinavian journal of gastroenterology. 1996;31(7):665-70.
Flint A, Raben A, Astrup A, Holst JJ. Glucagon-like peptide 1 promotes satiety and
suppresses energy intake in humans. J Clin Invest. 1998;101(3):515-20.
Gutzwiller JP, Drewe J, Göke B, Schmidt H, Rohrer B, Lareida J, et al. Glucagon-like
peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type
2. Am J Physiol. 1999;276(5):R1541-4.
Verdich C, Flint A, Gutzwiller JP, Näslund E, Beglinger C, Hellström PM, et al. A metaanalysis of the effect of glucagon-like peptide-1 (7-36) amide on ad libitum energy intake
in humans. J Clin Endocrinol Metab. 2001;86(9):4382-9.
23